Technical Analysis for MEIP - MEI Pharma, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Flat | Down |
| See historical MEIP trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Spinning Top | Other | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | 1.97% | |
| 200 DMA Resistance | Bearish | 2.30% | |
| Fell Below 20 DMA | Bearish | 2.30% | |
| Fell Below 50 DMA | Bearish | 2.30% | |
| Expansion Pivot Sell Setup | Bearish Swing Setup | 2.30% | |
| Slingshot Bullish | Bullish Swing Setup | 2.30% | |
| Down 3 Days in a Row | Weakness | 2.30% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/08/2019
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
MEI Pharma, Inc., a development stage oncology company, focuses on the clinical development of therapeutics for the treatment of cancer. It develops various lead drug candidates, including ME-143 that has completed Phase I clinical trials in patients with refractory solid tumors; ME-344, an active metabolite of NV-128, which is in Phase I clinical trials in patients with solid refractory tumors; and Pracinostat, an orally histone deacetylase inhibitor that has completed various Phase I clinical trials in patients with hematologic disorders. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. MEI Pharma, Inc. is a subsidiary of Novogen Limited. MEI Pharma, Inc. (NasdaqCM:MEIP) operates independently of Novogen Limited as of December 03, 2012.
Medicine Cancer Clinical Medicine Treatment Of Cancer Virotherapy Seattle Genetics Kite Pharma Hematologic Disorders Refractory Solid Tumors
Medicine Cancer Clinical Medicine Treatment Of Cancer Virotherapy Seattle Genetics Kite Pharma Hematologic Disorders Refractory Solid Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more MEIP news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 5.14 |
| 52 Week Low | 1.82 |
| Average Volume | 160,644 |
| 200-Day Moving Average | 3.2285 |
| 50-Day Moving Average | 3.1049 |
| 20-Day Moving Average | 3.115 |
| 10-Day Moving Average | 3.158 |
| Average True Range | 0.1623 |
| ADX | 14.21 |
| +DI | 18.5498 |
| -DI | 20.1665 |
| Chandelier Exit (Long, 3 ATRs ) | 2.9231 |
| Chandelier Exit (Short, 3 ATRs ) | 3.3169 |
| Upper Bollinger Band | 3.3265 |
| Lower Bollinger Band | 2.9035 |
| Percent B (%b) | 0.49 |
| BandWidth | 13.579454 |
| MACD Line | 0.0142 |
| MACD Signal Line | 0.0182 |
| MACD Histogram | -0.004 |
| Fundamentals | Value |
|---|---|
| Market Cap | 114.88 Million |
| Num Shares | 36.9 Million |
| EPS | 0.07 |
| Price-to-Earnings (P/E) Ratio | 44.43 |
| Price-to-Sales | 4.35 |
| Price-to-Book | 1.98 |
| PEG Ratio | 23.80 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.35 | ||||
| Resistance 3 (R3) | 3.34 | 3.25 | 3.31 | ||
| Resistance 2 (R2) | 3.25 | 3.19 | 3.26 | 3.30 | |
| Resistance 1 (R1) | 3.18 | 3.15 | 3.22 | 3.19 | 3.28 |
| Pivot Point | 3.09 | 3.09 | 3.11 | 3.10 | 3.09 |
| Support 1 (S1) | 3.02 | 3.03 | 3.06 | 3.03 | 2.94 |
| Support 2 (S2) | 2.93 | 2.99 | 2.94 | 2.92 | |
| Support 3 (S3) | 2.86 | 2.93 | 2.91 | ||
| Support 4 (S4) | 2.87 |
